Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.

Autor: Espeseth AS; Merck & Co., Inc., Rahway, New Jersey, USA., Yuan M; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Citron M; Merck & Co., Inc., Rahway, New Jersey, USA., Reiserova L; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Morrow G; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Wilson A; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Horton M; Merck & Co., Inc., Rahway, New Jersey, USA., Rukhman M; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Kinek K; Merck & Co., Inc., Rahway, New Jersey, USA., Hou F; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Li SL; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Li F; Merck & Co., Inc., Rahway, New Jersey, USA., Choi Y; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Heidecker G; Merck & Co., Inc., Rahway, New Jersey, USA., Luo B; Merck & Co., Inc., Rahway, New Jersey, USA., Wu G; Merck & Co., Inc., Rahway, New Jersey, USA., Zhang L; Merck & Co., Inc., Rahway, New Jersey, USA., Strable E; Merck & Co., Inc., Rahway, New Jersey, USA., DeStefano J; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Secore S; Merck & Co., Inc., Rahway, New Jersey, USA., Mukhopadhyay TK; Merck & Co., Inc., Rahway, New Jersey, USA., Richardson DD; Merck & Co., Inc., Rahway, New Jersey, USA., Sayeed E; The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA., Welch LS; The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA; Currently at Clover Biopharmaceuticals, Boston, Massachusetts, USA., Bett AJ; Merck & Co., Inc., Rahway, New Jersey, USA., Feinberg MB; The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA., Gupta SB; The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA., Cooper CL; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA., Parks CL; The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA. Electronic address: cparks@iavi.org.

Publikováno v: EBioMedicine [EBioMedicine] 2022 Aug; Vol. 82, pp. 104203. Date of Electronic Publication: 2022 Jul 30.

Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.

Autor: Secore S; Vaccine Basic Research, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Wang S; Vaccine Basic Research, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Doughtry J; Vaccine Basic Research, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Xie J; Vaccine Basic Research, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Miezeiewski M; Eurofins Laboratories, Lancaster, Pennsylvania, United States of America., Rustandi RR; Vaccine Analytical Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Horton M; Vaccine Basic Research, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Xoconostle R; Vaccine Basic Research, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Wang B; Vaccine Drug Product Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Lancaster C; Vaccine Analytical Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Kristopeit A; Vaccine Process Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Wang SC; Vaccine Process Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Christanti S; Vaccine Process Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Vitelli S; Vaccine Analytical Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Gentile MP; Vaccine Process Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Goerke A; Vaccine Process Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Skinner J; Vaccine Basic Research, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Strable E; Vaccine Drug Product Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Thiriot DS; Vaccine Drug Product Development, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Bodmer JL; Vaccine Basic Research, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America., Heinrichs JH; Vaccine Basic Research, Merck Research Laboratories, Merck and Company, Incorporated, West Point, Pennsylvania, United States of America.

Publikováno v: PloS one [PLoS One] 2017 Jan 26; Vol. 12 (1), pp. e0170640. Date of Electronic Publication: 2017 Jan 26 (Print Publication: 2017).

Magnetic Hyperthermia Therapy for High-Grade Glioma: A State-of-the-Art Review.

Autor: Rodriguez, Benjamin^1,2 (AUTHOR) benjamin.rodriguez@icahn.mssm.edu, Rivera, Daniel¹ (AUTHOR) jack.zhang@icahn.mssm.edu, Zhang, Jack Y.¹ (AUTHOR) cole.brown@icahn.mssm.edu, Brown, Cole¹ (AUTHOR) tirone.young@icahn.mssm.edu, Young, Tirone^1,2 (AUTHOR), Williams, Tyree^2,3 (AUTHOR), Huq, Sakibul⁴ (AUTHOR), Mattioli, Milena⁵ (AUTHOR) mattiolim3@upmc.edu, Bouras, Alexandros⁵ (AUTHOR) bourasa@upmc.edu, Hadjpanayis, Constantinos G.^4,5,6 (AUTHOR) benjamin.rodriguez@icahn.mssm.edu

Publikováno v: Pharmaceuticals (14248247). Mar2024, Vol. 17 Issue 3, p300. 17p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.